Because BCC and cSCC have high tumor mutational burdens driven by UV-induced DNA damage, they are particularly well suited to immune checkpoint inhibition.
Joshua Burshtein, MD
Advertisement
Joshua Burshtein, MD, is a resident physician in the Department of Dermatology at the University of Illinois Chicago.
Articles by Joshua Burshtein, MD
A phase 2 clinical trial found that topical ruxolitinib cream showed promising efficacy and safety in patients with mild to moderate hidradenitis suppurativa.
IL-17 inhibitors are highly effective, but many patients still require switching due to treatment failure, loss of response, or intolerance.
Discover the latest breakthroughs in atopic dermatitis and psoriasis treatments for 2025, enhancing patient care and individualizing therapy options.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Dermatology Times
1
Chronic Hand Eczema: Treatment Gaps, New Options, and Clinical Trial End Points
2
Mona Shahriari, MD, FAAD: Matching the Right AD Therapy to the Right Patient
3
The Side Effect of Doing Nothing: Reframing Atopic Dermatitis as a Systemic Disease
4
Elaine Siegfried, MD, Highlights Evolving Pediatric AD Care and Remaining Treatment Gaps
5